A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Juliana Hutchinson, MSc
- Telefonnummer: +4161 551 75 75
- E-post: clinical.trial.enquiry@windwardbio.com
Studiesteder
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, Argentina, C1023AAB
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1028AAP
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1122AAK
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425BEN
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425FVH
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C142ABP
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1414AIF
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires F.D., Argentina, C1426ABP
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Mendoza Province
-
Buenos Aires, Mendoza Province, Argentina, M5500AXR
- Rekruttering
- WB Contracted Clinical Research Site
-
Mendoza, Mendoza Province, Argentina, M5500CBA
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000KZD
- Rekruttering
- WB Contracted Clinical Research Site
-
Rosario, Santa Fe Province, Argentina, S2013OJN
- Rekruttering
- WB Contracted Clinical Research Site
-
Santa Fe, Santa Fe Province, Argentina, S3000ASF
- Rekruttering
- WB Contracted Clinical Research Site
-
-
-
-
California
-
Los Angeles, California, Forente stater, 93534
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Florida
-
Miami Lakes, Florida, Forente stater, 33014
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Forente stater, 02747
- Rekruttering
- WB Contracted Clinical Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28277
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Oregon
-
Medford, Oregon, Forente stater, 97504
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, Forente stater, 15801
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Texas
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- WB Contracted Clinical Research Site
-
Waxahachie, Texas, Forente stater, 75165
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adults aged 40 to 80 years
- Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
- On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
- Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
- Elevated eosinophil count
- Weight/BMI within allowed range
Exclusion Criteria:
- Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
- Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
- Clinically significant cardiovascular disease
- Recent respiratory infection or COPD exacerbation
- Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
- Pregnancy or breastfeeding
- Smoking or diagnosed substance use disorder
- Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: WIN378 Dose 1
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Eksperimentell: WIN378 Dose 2
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Eksperimentell: Placebo
Placebo SC injections will be administered
|
Placebo matching WIN378
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Number of participants with Serious Adverse Events (SAEs)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in systolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in diastolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in pulse rate (beats/minute)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in respiratory rate (breaths/minute)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in oxygen saturation (%)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body weight (kg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body mass index (kg/m^2)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body temperature (°C)
Tidsramme: Week 0- Week 36
|
Week 0- Week 36
|
|
|
Change from baseline in clinical chemistry laboratory assessments
Tidsramme: Week 0 - Week 36
|
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
|
Week 0 - Week 36
|
|
Change from baseline in haematology laboratory parameters
Tidsramme: Week 0 - Week 36
|
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
|
Week 0 - Week 36
|
|
Change from baseline in coagulation laboratory parameters
Tidsramme: Week 0 - Week 36
|
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
|
Week 0 - Week 36
|
|
Change from baseline in urinalysis parameters
Tidsramme: Week 0 - Week 36
|
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
|
Week 0 - Week 36
|
|
Change from baseline in electrocardiogram QT interval
Tidsramme: Week 0 - Week 36
|
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
|
Week 0 - Week 36
|
|
WIN378 Serum concentration (PK)
Tidsramme: Week 0 to week 36
|
Week 0 to week 36
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in Blood Eosinophil Count
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Incidence and magnitude of anti-drug antibodies to WIN 378
Tidsramme: Week 0 to Week 36
|
Week 0 to Week 36
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Omar Khwaja, MD, Windward Bio
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- WB-2102
- U1111-1333-4974 (Annen identifikator: UTN, World Health Organization (WHO))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .